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Purpose: To evaluate the association of five different polymorphisms from a genome-
wide-associated study with susceptibility to glaucoma in the northeast Iranian popula-
tion.
Methods: Hundred and thirty patients with primary angle closure glaucoma (PACG) and
130 healthy controls were genotyped for the polymorphic regions with the aid of tetra-
amplification refractory mutation system-polymerase chain reaction. The association of
these variants with the disease susceptibility was measured statistically with the logistic
regression method.
Results: Hundred and thirty patients with PACG (53 males, 77 females) with a mean
age of 64.5 ± 6.2 years and 130 healthy control subjects (51 males, 79 females) with
a mean age of 64.0 ± 5.7 years were selected for evaluation. There was a significant
association between rs3816415 (P = 0.005), rs736893 (P < 0.001), rs7494379 (P < 0.001),
and rs1258267 (P = 0.02) with PACG susceptibility. This association could not be shown
for rs3739821.
Conclusion: It was revealed that studied variants in GLIS3, EPDR1, FERMT2, and CHAT
genes can contribute to the incidence of PACG. Additional studies in other populations
are needed to evaluate DPM2-FAM102A.
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Glaucoma is one of the leading causes of blind-
ness worldwide. Approximately 70 million people
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are affected and it is predicted that by 2020, this
number will rise to around 79.6 million globally.[1]
The incidence of glaucoma varies in different
populations and geographic regions.While primary
open-angle glaucoma (POAG) is the most common
type, primary angle closure glaucoma (PACG) is
associated with a more severe presentation and
bilateral blindness.[2–4] The visual function in PACG
could be saved if early and proper treatments are
adopted.[5]
PACG is characterized by apposition between
the peripheral iris and trabecular meshwork, which
can ultimately lead to compromised outflow and
high intraocular pressure (IOP).[6] Stress induced
by IOP on optic disc results in compression, defor-
mation, and remodeling of the lamina cribrosa
with subsequent mechanical axonal damage and
disruption of axonal transport or ischemic damage
to the neural tissue.[7]
PACG is a complex disease influenced by a
combination of environmental and genetic risk fac-
tors. Recently, COL18A1, which encodes collagen
type XVIII, has been identified as a gene that
affects angle closure in humans and can lead to
PACG.[8] An unusually higher incidence among first-
degree relatives of affected patients compared
with the general population suggests that genetic
risk factors may play an important role in the devel-
opment of PACG.[9, 10] Another factor indicating
a genetic influence in PACG development is the
heritability for narrow-angle and a shallow anterior
chamber (two important causes of disease) that are
approximately 49% and 93%, respectively.[9, 11]
Although several genome-wide association
studies (GWASs) for PACG revealed multiple
genetic variants correlated with disease
susceptibility, these results demonstrate that
the exact mechanisms by which the culprit gene
could cause PACG is not completely understood
and the association of different single nucleotide
polymorphisms (SNPs) with glaucoma are still
controversial.[12, 13]
Among different reported variants, expression
quantitative trait locus (eQTL) mapping databases
indicate that rs7494379 on chromosome 14 posi-
tion 53,411,391, gene locus FERMT2, rs736893
on chromosome 9 position 4,217,028, gene locus
GLIS3, rs1258267 on chromosome 10 position
50,895,770, gene locus CHAT, rs3816415 on
chromosome 7 position 37,988,311, gene locus
EPDR1, and rs3739821 on chromosome 9 position
130,702,477, gene locus DPM2-FAM102A are sig-
nificantly expressed in ocular anterior segment
tissues such as iris, ciliary body, and trabecular
meshwork,[14, 15] which mark them as potential vari-
ants for PACG incidence.
The current study aimed to evaluate the associ-
ation of these five SNPs evaluated in GWAS with
PACG susceptibility in the northeast of Iran.
METHODS
Population study
This case-control study was conducted on sub-
jects that were following up for PACG at Khatam
Eye Hospital, a referral eye center in Mashhad,
northeast of Iran, between 2017 and 2018. The
case group included 130 patients with PACG that
were diagnosed and followed by a glaucoma-
trained ophthalmologist according to optic nerve
exam, gonioscopy, IOP, and visual field changes
and completed the interview of competency (53
males and 77 females). Individuals with primary
angle closure and primary angle closure suspect
(with only obstructed angle and/or increased IOP
with no obvious optic nerve cupping or visual
field defect) were not selected for the study and
only patients with established optic nerve, head
damage, or glaucomatous perimetric changes due
to PACG were considered for evaluation. Control
subjects were 130 healthy individuals (51 males
and 79 females)[16] without any glaucoma findings
or signs of angle closure in gonioscopy. Clinical
information including age and sex was gathered.
The Ethics Committee of the Mashhad University
of Medical Sciences approved the study.
SNP selection criteria
The analyzed polymorphisms were selected on the
basis of recent GWAS analysis and the databases
prepared on the National Center for Biotechnology
Information SNP Database (https://www.ncbi.nlm.
nih.gov/snp/) (Access date: Dec 20, 2018) and lit-
erature searches. We selected five validated SNPs
with a minor allele frequency >1%.[17, 18]
Genotyping
DNA was extracted from the whole blood
using the standard salting-out method
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which was previously described by Miller
et al.[19] Genotyping was carried out by tetra-
amplification refractory mutation system-
polymerase chain reaction (tetra-ARMS PCR).
For amplification of the sequences containing
polymorphic site, compatible and specified
primers were designed using GeneRunner v3.01
(http://generunner.net/) and NCBI BLAST was used
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/)
for ensuring the specificity. Properties of designed
primers are listed in Table 1.
PCR reaction was performed in a final volume
of 15 𝜇l consisting 100 ng genomic DNA, 8 𝜇l of
PCR master mix (Ampliqon A/S, Stenhuggervej 22,
DK-5230 Odense M, Denmark), 0.5 𝜇M of inner
primers, and 0.25 𝜇M of outer primers. Amplified
products were visualized by 2% agarose gel elec-
trophoresis. To confirm the results, 10% of samples
were randomly re-genotyped by direct sequencing
on ABI3130xl genetic analyzer (Thermo Fisher
Scientific, USA) and the results were reproducible,
with no discrepancy.
Statistical analysis
Chi-square test was used for determining the
statistical significance of non-association between
different variables. Logistic regression analysis was
performed to estimate the association between
polymorphism variants and the risk of PACG in
different genders. The odds ratios (OR) and 95%
confidence intervals (CI) were adjusted. Reported
P-values were two-sided and the significance level
was considered < 0.05. The SPSS, version 23.0
program (SPSS, Inc., Chicago, IL) was used for
statistical analysis.
Results
This study included 130 patients with PACG (mean
age: 64.5 ± 6.2 years) and 130 healthy control
subjects (mean age: 64.0 ± 5.7 years). Age and sex
of the participants were comparable between the
two groups (P > 0.05). Detailed properties of the
study subjects are demonstrated in Table 2.
The tetra-ARMS PCR method was successfully
applied to genotype five different SNPs. The asso-
ciation of genotypes and allelic frequencies of
five polymorphisms with PACG was determined.
Genotype frequencies of all tested polymorphisms
were in Hardy–Weinberg equilibrium. Genotype
frequencies of analyzed SNPs are demonstrated in
Table 3.
As evident in Table 3, a highly significant asso-
ciation and perhaps predisposing effect was found
for G/A genotype of rs736893 in the GLIS3 gene
and T/T genotype of rs7494379 in the FERMT2
gene (P < 0.001). Statistically meaningful associa-
tion of rs1258267 in the CHAT gene and rs3816415
in the EPDR1 gene with PACG was also confirmed,
but rs3739821 in the DPM2-FAM102A genes did
not have any significant association with PACG
frequency in our study population.
The correlation of rs736893, rs1258267, and
rs7494379 with the disease was stronger in males
than in females, and rs3816415 had more associa-
tion with the disease in females [Table 4].
Overall, a highly significant (P < 0.001) predis-
posing effect for the C/T genotype of rs3816415 in
the EPDR1 gene and G/A genotype of rs736893 in
the GLIS3 was observed [Table 3]. Genotype fre-
quency analysis revealed that heterozygote geno-
type in rs736893, A/A genotype in rs1258267, C/C
genotype in rs3816415, and heterozygote geno-
type in rs3739821 were more frequent. However,
genotype distribution in rs7494379 was not con-
sistent and C/C genotype and C/T genotype were
more frequent in cases and controls, respectively.
DISCUSSION
The results of the present study reveal significant
differences in the frequencies of genotypes of
EPDR1, GLIS3, CHAT, and FERMT2 polymorphisms
between PACG patients and controls. The signifi-
cantly higher frequencies of genotypeG/A of GLIS3
and C/T of EPDR1 in patients with PACG than those
in the controls indicated that these genotypes may
be associated with a susceptibility to this disease.
Previous studies showed controversial results
on the association of PACG with genetic variants
investigated in the current study. Zhuang et al
found that only SNPs rs3753841 in COL11A1,
rs1258267 in CHAT, and rs736893 in GLIS3
are associated with PACG in northern Chinese
people; however, other studies demonstrated
EPDR1, GLIS3, CHAT, FERMT2, and DPM2-
FAM102A polymorphisms contribution to the
disease susceptibility.[12, 18, 20]
FERMT2 encodes a protein called pleckstrin-
homology-domain-containing family C member
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Table 1. Tetra-ARMS primer details.
SNP Sequence Product length (nucleotide) Tm (degree centigrade)




















SNP, single nucleotide polymorphism
Table 2. Characteristics of the study groups
Study Groups PACG patients Control Group P-value
Number of Subjects 130 130
Gender 0.450
Male, n (%) 53(40.8) 51(39.2)
Female, n (%) 77(59.2) 79(60.8)
Age (years)
Mean (SD) 64.5(6.2) 64.0(5.7) 0.657
n, number; PACG, primary angle closure glaucoma; SD, standard deviation
1 (PLEKHC1), a component of the extracellular
matrix, and could thus have a role in cell adhe-
sion; cell–cell adhesion has been proposed as
an important process in the pathogenesis of
PACG.[21] GLIS3 is a member of the GLI-similar
subfamily of Krüppel-like zinc-finger proteins.[22]
Earlier studies have shown that mutations in
GLIS3 cause neonatal diabetes and congenital
hypothyroidism.[23] SNP markers mapping close
to GLIS3 have been observed to be significantly
associated with type 1 diabetes in Europeans
(rs7020673),[24] type 2 diabetes in East Asians
(rs7041847),[25] and fasting plasma glucose lev-
els in a large meta-analysis of European collec-
tions (rs7034200);[26] however, metabolic path-
ways through which zinc-finger activation could
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Table 3. Genotype frequencies
Genotypes Snps PACG patients N (%) Controls N (%) OR (95%CI) P-value
rs736893 < 0.001
G/G 10(7.6) 46(35.3) Reference Reference
G/A 120(92.4) 84(64.7) 6.77(3.2–14.2) < 0.001
A/A 0 0 – –
rs1258267 0.02
A/A 97(74.6) 113(86.9) Reference Reference
A/G 30(23) 17(13.1) 2(1–3.9) 0.033
G/G 3(2.4) 0 1.5(1.3–1.7) 0.078
rs3816415 0.005
C/C 120(92.3) 129(99.2) Reference Reference
C/T 10(7.7) 1(0.8) 10.75(1.3-85.4) 0.025
T/T 0 0 – –
rs3739821 0.42
T/T 28(21.5) 23(17.6) Reference Reference
T/C 79(60.7) 76(58.4) 1.69(0.7–3.7) 0.18
C/C 23(17.8) 31(24) 1.46(0.7–2.7) 0.23
rs7494379 < 0.001
C/C 48(36.9) 80(61.5) Reference Reference
C/T 50(38.4) 37(28.4) 2.28(1.3-3.9) 0.004
T/T 32(24.7) 13(10.1) 4.08(1.9-8.5) < 0.001
contribute to pathogenesis of PACG is not well
understood.[12]
CHAT on chromosome 10 encodes choline
acetyltransferase, an enzyme responsible for the
synthesis of the neurotransmitter acetylcholine,
which has a role in pupillary constriction. Anti-
cholinergic medications can precipitate acute
PACG through pupillary dilatation mechanisms
and subsequent pupillary block. Therefore, it is
plausible that natural genetic variation in a gene
influencing acetylcholine metabolism could alter
the risk for PACG.[27]
EPDR1 encodes a glycosylated type II trans-
membrane protein known as ependymin-related
1. It potentially has a role in cell adhesion,
and it has some similarity to protocadherins and
ependymins.[26] As mentioned earlier, disturbance
in cell–cell adhesion could have some roles in the
pathogenesis of PACG.[12]
SNP rs3739821 is located in an intergenic region
between DPM2 and FAM102A, a gene yet to be
fully characterized. Mutations in DPM2 have been
linked to congenital defects in glycosylation,[28]
leading to severe pathological neurological phe-
notypes. Although not much is known about
FAM102A, except that its expression is sensitive
to the addition of 𝛽-estradiol, the nearby PIP5KL1
gene has been reported to be involved in cell
proliferation[29] and potentially in tumorigenesis.
Expression analysis revealed that all three genes
(FAM102A, DPM2, and PIP5KL1) were expressed
in all eye tissues tested, thus providing bio-
logical support for their potential role in PACG
development.[12]
The expression of all these genes in the cornea,
lens, retina, choroid, and optic nerve head confirms
the function of these genes in these tissues.[12]
The activity of these genes products in the ocular
system can explain howdifferent variations in these
genes may contribute to the PACG.
In conclusion, characterizations of these varia-
tions suggest that they can contribute to PACG sus-
ceptibility; however, the penetrance of the alleles
may be low. Being able to divide the population
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Table 4. Genotype frequencies in male and female groups
Genotypes Gender PACG patients N (%) Controls N (%) OR (95%CI) P-value
rs736893 <0.001
G/G Male 5(9) 19(37) Reference Reference
G/A 48(91) 32(63) 5(1.5–16.5) 0.007
A/A 0(0) 0(0) – –
G/G Female 5(7) 27(34) Reference Reference
G/A 72(93) 52(66) 7(2.5–22.2) 0.01
A/A 0(0) 0(0) – –
rs1258267 0.02
A/A Male 39(74) 43(84) Reference Reference
A/G 12(22) 8(16) 2.7(0.8–9.2) 0.1
G/G 2(4) 0(0) 10(0.1–11.1) 0.98
A/A Female 58(75) 70(89) Reference Reference
A/G 18(23) 9(11) 1.5(0.6–4) 0.3
G/G 1(2) 0(0) 11(0.6–27.4) 0.8
rs3816415 0.005
C/C Male 47(89) 51(11) Reference Reference
C/T 6(11) 0(0) 18(0.2–23.4) 0.98
T/T 0(0) 0(0) – –
C/C Female 73(95) 78(99) Reference Reference
C/T 4(5) 1(1) 3.6(0.3–25.4) 0.2
T/T 0(0) 0(0) – –
rs3739821 0.42
T/T Male 12(23) 5(10) Reference Reference
T/C 28(53) 31(61) 0.4(0.1–1.5) 0.19
C/C 13(24) 15(29) 0.3(0.1–1.3) 0.11
T/T Female 16(21) 18(23) Reference Reference
T/C 15(66) 45(57) 1(0.4–2.6) 0.83
C/C 10(13) 16(20) 0.7(0.2–2.4) 0.66
rs7494379 < 0.001
C/C Male 16(31) 32(63) Reference Reference
C/T 22(41) 14(27) 2.6(0.9–7.4) 0.063
T/T 15(75) 5(10) 8.4(2.2–32.1) 0.002
C/C Female 32(42) 48(61) Reference Reference
C/T 28(36) 23(29) 1.6(0.7–3.5) 0.2
T/T 17(22) 7(10) 3(1–8.8) 0.04
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into risk categories would allow tailored screening,
prognosis, and treatment programs according to
the risk of each individual. Additional studies in
other populations with more participants should be
considered to evaluate the association of DPM2-
FAM102A with the disease.
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